EP0028 / Innolake Biopharma, Ellipses Pharma - LARVOL DELTA

Ellipses Pharma Limited…announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd ('Innolake') to develop a clinical stage first-in-class antibody drug conjugate (ADC) (Businesswire) - "Under the partnership, Ellipses gains rights to develop a B7H3 targeted ADC with an eribulin payload (ILB-3101) worldwide excluding greater China. ILB-3101 has the potential to treat multiple tumour types and to address resistance to topoisomerase-1 based ADCs. ILB-3101 is designated as EP0028 by Ellipses....Ellipses will initiate a Phase 1 clinical trial in the US with expansion to Europe and other territories following relevant regulatory approvals."

Licensing / partnership • New P1 trial • Solid Tumor

A Study of the ILB-3101 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Innolake Biopharm | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2024 ➔ Oct 2024

Enrollment open • Metastases • Trial initiation date • Oncology • Solid Tumor

A Study of the ILB-3101 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=240 | Not yet recruiting | Sponsor: Innolake Biopharm

New P1 trial • Oncology • Solid Tumor

ILB-3101, a novel B7H3-targeting ADC with Eribulin as payload, demonstrates strong tumor killing activities and favorable PK/TOX profile in preclinical evaluation (AACR 2024) - "It also shows better internalization than benchmark antibodies such as that of DS-7300 analog. ILB-3101 is worthy of further translational research and clinical trials. Its IND application has been submitted in China, followed by US FDA filing soon."

Preclinical • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • CD276